Online vs. Local GLP-1 Provider: Which Is Right for You?

The Short Answer

There are now three ways to get a GLP-1, not two, and the third one is new enough that most comparison guides still don't mention it.

Buying direct from the manufacturer costs $149 to $449 a month depending on the drug, and it did not exist as a mainstream option two years ago. Online telehealth runs $99 to $548 a month across the platforms we track and adds a clinician plus coaching. A local clinic costs the most and is the only one that examines you in person.

If your health picture is straightforward and cost is the deciding factor, compare the manufacturer's own price against the telehealth platforms before assuming telehealth wins — since December 2025 it often doesn't. If you have other conditions in the mix, take several medications, or have had a rough time with side effects before, a local clinic earns its premium.

What each one actually gets you

The three-way gap is much narrower than the old two-way one. Novo publishes $349 a month for standard Wegovy doses. Lilly publishes $299 to $449 for Zepbound vials and $149 for the lowest dose of Foundayo, its oral GLP-1. Those are brand-name, FDA-approved products at prices that used to be compounded-only territory.

When buying direct is the right call

You already have a prescription and don't need ongoing support. The manufacturers' pharmacies sell to you at a published price. You still need a prescriber, but you are not paying a platform's monthly fee on top.

You want an FDA-approved product, full stop. Everything sold direct is the approved drug with the approved label, which removes the sourcing question entirely.

You are price-comparing honestly. A telehealth platform above roughly $350 a month is charging you for the consultation, the coaching and the convenience rather than for the medication. Those things have real value — just know which one you are buying.

Read the refill conditions. Lilly's published Zepbound prices assume you refill within 45 days of your previous delivery. Miss that window and the two highest doses jump to $849 and $1,049 a month. That is the kind of term that quietly doubles a budget.

When online telehealth is the right call

You need the prescriber and the medication in one place. This is the real product: a licensed clinician, a prescription, and delivery, without assembling it yourself.

You're generally healthy and your goal is straightforward weight loss. For an otherwise-healthy adult who meets the BMI criteria, the streamlined model works well.

Your schedule, or your town, makes office visits hard. If the nearest clinic is 45 minutes away, adherence suffers. The medication you actually take beats the clinic you stop visiting.

You want coaching alongside the prescription. Several platforms include dietitian access, behaviour coaching and unlimited messaging. That is worth paying for if you will use it.

Ask two questions before you pay. Which medication am I actually getting, and is the quoted price the all-in price? Some platforms quote a low membership and bill medication separately — which can still be the cheapest route, but only if you do the addition yourself. Our ranked provider comparison scores every platform on exactly this.

When a local clinic is worth the premium

You have other health conditions in the mix. Diabetes, heart or kidney conditions, a history of pancreatitis or gallbladder disease, thyroid concerns, several daily medications — the more complex the picture, the more valuable a provider who examines you and can react quickly.

You've had a rough time with side effects before. GLP-1 side effects are usually manageable, but if nausea or dehydration has landed you in trouble before, in-person monitoring and same-week appointments matter.

You want the full metabolic program. The best local clinics pair medication with body-composition tracking, nutrition counselling and strength-training guidance — the things that protect muscle while you lose weight. That bundle is hard to replicate over video.

You want continuity. One provider who knows your history and adjusts your plan over months is a genuinely different product from a rotating cast of telehealth clinicians.

What changed, and why old advice is out of date

Until 2025 the honest answer to this question was simple: telehealth, because compounded semaglutide made it far cheaper than anything else. That answer has expired.

The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. Those declarations ended the exemption that allowed compounding pharmacies to mass-produce copies, and every wind-down deadline had passed by May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on the grounds that there is "no clinical need" for outsourcing facilities to compound them.

Meanwhile the manufacturers opened their own cash-pay pharmacies, and prices that used to require a compounded product now buy the approved one.

The practical effect: a platform still advertising compounded semaglutide or tirzepatide is operating in a narrower and more contested space than it was two years ago. In March 2026 the FDA sent warning letters to 30 telehealth companies over how they market compounded GLP-1s, objecting to "claims implying sameness with FDA-approved products" and to firms "obscuring product sourcing by advertising drug products branded with the telehealth firm's name." No companies were named in that announcement. Ask any provider directly which pharmacy fills your prescription and on what basis.

Red flags, in all three models

• No labs, ever. Any provider who prescribes GLP-1s without baseline labwork is cutting a corner that exists for your safety.
• No licensed clinician visit. A questionnaire alone is not an evaluation. Somewhere in the process, a licensed provider should actually talk to you.
• Mystery medication sourcing. A provider should tell you which pharmacy fills your prescription. If they won't name it, that is the answer.
• A house-branded drug. If a platform sells the medication under its own brand rather than naming the drug and the pharmacy, that is precisely what the FDA's March 2026 letters were about.
• Pressure to prepay many months. Dose changes and side effects are normal parts of treatment. Check what happens to a prepaid plan if you stop.

See How to Choose a GLP-1 Clinic for the full checklist.

The hybrid approach

Plenty of people mix these. Start at a local clinic for the workup, exam and first months of titration, then move to a cheaper route for stable maintenance dosing. Or start online for speed and move to a local clinic if side effects or plateaus call for closer management. Nothing about this choice is permanent.

The bottom line

Compare all three: browse local clinics by city, see our ranked telehealth comparison, or read the GLP-1 Price Guide for the full cost breakdown including insurance and manufacturer savings programs.

Sources

• FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — shortage resolution dates and wind-down deadlines.
• FDA — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — April 30, 2026.
• FDA — FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s — March 3, 2026.
• Novo Nordisk / NovoCare — Wegovy self-pay price guide (PDF)
• Eli Lilly — Lilly lowers the price of Zepbound single-dose vials — December 1, 2025, including the 45-day refill condition.
• Eli Lilly — FDA approves Foundayo (orforglipron) — April 1, 2026, LillyDirect self-pay from $149/month.
• CMS — Medicare GLP-1 Bridge
• Telehealth platform pricing: each company's published pricing pages, checked August 25, 2026 and recorded in the VitalityMatch provider directory.

*Every figure above was verified against the source linked beside it on the date shown at the top of this guide. This is not medical advice — talk to a licensed clinician before starting or changing any treatment.*